SGLT2抑制剂与2型糖尿病患者癌症风险:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析检索截至2017年2月15日的随机对照试验,纳入46项试验、34,569例2型糖尿病患者,共580例癌症发生。SGLT2抑制剂与总体癌症风险无显著相关(OR 1.14,95%CI 0.96, 1.36),但膀胱癌风险可能升高(OR 3.87,95%CI 1.48, 10.08),尤其是恩格列净(OR 4.49,95%CI 1.21, 16.73);卡格列净可能对胃肠道癌症有保护作用(OR 0.15,95%CI 0.04, 0.60)。
要点
- SGLT2抑制剂与总体癌症风险无显著相关(OR 1.14,95%CI 0.96, 1.36)。
- 膀胱癌风险可能升高(OR 3.87,95%CI 1.48, 10.08),尤其是恩格列净(OR 4.49,95%CI 1.21, 16.73)。
- 卡格列净可能对胃肠道癌症有保护作用(OR 0.15,95%CI 0.04, 0.60)。
核心结论
- 现有短期随机对照试验证据未显示2型糖尿病患者使用SGLT2抑制剂总体癌症风险显著增加。
- 鉴于试验持续时间短且证据存在不确定性,需要未来的长期前瞻性研究和上市后监测研究。
研究设计与样本
- 系统检索PubMed、EMBASE、Cochrane对照试验中心注册库和ClinicalTrials.gov,检索时间从建库至2017年2月15日。
- 纳入报告2型糖尿病患者使用SGLT2抑制剂至少24周癌症事件的随机对照试验。
- 共纳入46项独立随机对照试验,34,569例个体,580例癌症发生,平均试验持续时间61周。
- 进行配对和网络Meta分析以及累积Meta分析,计算OR和95%CI。
主要发现
- 与对照(安慰剂或其他活性降糖治疗)相比,SGLT2抑制剂与总体癌症风险增加无显著相关(OR 1.14,95%CI 0.96, 1.36)。
- 预设癌症类型中,SGLT2抑制剂可能增加膀胱癌风险(OR 3.87,95%CI 1.48, 10.08),尤其是恩格列净(OR 4.49,95%CI 1.21, 16.73)。
- 卡格列净可能对胃肠道癌症有保护作用(OR 0.15,95%CI 0.04, 0.60)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出试验持续时间短,证据存在不确定性。
- 原文结论提出需要未来的长期前瞻性研究和上市后监测研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the risk of cancer in individuals with type 2 diabetes remains uncertain. This study aimed to evaluate the risk of cancer associated with SGLT2 inhibitor treatment of type 2 diabetes. METHODS: We systematically searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov from inception to 15 February 2017 to identify eligible randomised controlled trials (RCTs) that report cancer events in individuals with type 2 diabetes treated with SGLT2 inhibitors for at least 24 weeks. We performed pairwise and network meta-analyses as well as a cumulative meta-analysis to calculate ORs and 95% CIs. RESULTS: In total, 580 incidences of cancer among 34,569 individuals were identified from 46 independent RCTs with a mean trial duration of 61 weeks. When compared with comparators (placebo or other active glucose-lowering treatments), SGLT2 inhibitors were not significantly associated with an increased risk of overall cancer (OR 1.14 [95% CI 0.96, 1.36]). For pre-specified cancer types, the risk of bladder cancer might be increased with SGLT2 inhibitors (OR 3.87 [95% CI 1.48, 10.08]), especially empagliflozin (OR 4.49 [95% CI 1.21, 16.73]). Interestingly, canagliflozin might be protective against gastrointestinal cancers (OR 0.15 [95% CI 0.04, 0.60]). CONCLUSIONS/INTERPRETATION: Current evidence from short-term RCTs did not indicate a significantly increased risk of overall cancer among individuals with type 2 diabetes using SGLT2 inhibitors. Given the short-term trial durations and uncertainty of evidence, future long-term prospective studies and post-marketing surveillance studies are warranted.
引用
- Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017. PMID: 28725912. doi:10.1007/s00125-017-4370-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。